Gilead Sciences Aktie 935700 / US3755581036
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
07.11.2025 14:54:55
|
Gilead's Livdelzi Shows Consistent Efficacy, Safety Outcomes In Primary Biliary Cholangitis Patients
(RTTNews) - Gilead Sciences, Inc. (GILD), Friday announced new long-term data, supporting Livdelzi's consistent efficacy and safety outcomes in patients with primary biliary cholangitis, a chronic, autoimmune disease of the bile ducts.
The real-world data analyzed 396 patients. Of these total patients, 130 switched from obeticholic acid and 266 used Livdelzi as second-line or monotherapy.
Presented at The Liver Meeting, the findings observed reductions in alkaline phosphatase or ALP in both groups, with most patients achieving ALP levels below 1.67×ULN.
Moreover, safety labs remained stable, and 93 percent of patients continued Livdelzi treatment throughout the observation period.
These data underscore Livdelzi's potential as an effective and well-tolerated alternative for patients switching from obeticholic acid, and as a second-line therapy.
Meanwhile, new interim results from the open-label Phase 3 ASSURE trial show that 67 percent of participants with PBC achieved a composite biochemical response, while 34 percent reached normalized ALP levels after three years of treatment with Livdelzi.
Further, new data from the pivotal RESPONSE study and its open-label extension, ASSURE, showed that Livdelzi delivers sustained and meaningful reduction in chronic itch.
In the pre-market hours, GILD is trading at $124.30, up 0.73 percent on the Nasdaq.
Nachrichten zu Gilead Sciences Inc.
|
14.11.25 |
NASDAQ Composite Index-Wert Gilead Sciences-Aktie: So viel Gewinn hätte ein Gilead Sciences-Investment von vor 10 Jahren abgeworfen (finanzen.ch) | |
|
13.11.25 |
Verluste in New York: NASDAQ 100 schlussendlich mit Abgaben (finanzen.ch) | |
|
13.11.25 |
Donnerstagshandel in New York: So bewegt sich der NASDAQ 100 am Nachmittag (finanzen.ch) | |
|
13.11.25 |
NASDAQ-Handel So performt der NASDAQ 100 mittags (finanzen.ch) | |
|
13.11.25 |
NASDAQ-Handel NASDAQ 100 startet in der Verlustzone (finanzen.ch) | |
|
11.11.25 |
Schwacher Handel: NASDAQ 100 legt zum Handelsende den Rückwärtsgang ein (finanzen.ch) | |
|
07.11.25 |
Zurückhaltung in New York: NASDAQ 100 liegt zum Ende des Freitagshandels im Minus (finanzen.ch) | |
|
07.11.25 |
NASDAQ Composite Index-Papier Gilead Sciences-Aktie: So viel hätten Anleger an einem Gilead Sciences-Investment von vor 5 Jahren verdient (finanzen.ch) |